Objective To explore the clinical effect of Xuefu Zhuyu Decoction combined with entecavir for the treatment of patients with hepatitis B compensated liver cirrhosis in blood stasis and collaterals blocking type. Methods A total of 80 patients with hepatitis B compensated liver cirrhosis in blood stasis and collaterals blocking type were selected, and they were randomly divided into observation group or control group, with 40 cases in each group. The observation group was treated with Xuefu Zhuyu Decoction combined with entecavir, while the control group was treated with entecavir. Both groups received 24⁃week course of treatment. The incidence rate of decompensated liver cirrhosis, HBV⁃DNA carrying capacity, liver function with respect to ALT, AST, total bilirubin (TBIL), serum inflammatory factors in terms of tumor necrosis factor α (TNF⁃α), interleukin (IL)⁃6, IL⁃22, liver ultrasound related indices (inner diameter of the main portal vein, splenic vein inner diameter, splenic thickness, splenic length), Traditional Chinese Medicine syndrome score and Traditional Chinese Medicine syndrome efficacy before and after treatment, as well as the occurrence of adverse reactions during treatment were compared debetween patients of the two groups. Results There was no statistically significant difference in the incidence rate of decompensated liver cirrhosis, inner diameter of the main portal vein, splenic vein inner diameter, splenic thickness, and splenic length between patients of the two groups 12 and 24 weeks after treatment (P>0.05). The levels of serum ALT, AST, TBIL, TNF⁃α, IL⁃6, IL⁃22, and HBV⁃DNA carrying capacity, Traditional Chinese Medicine syndrome score decreased with the prolonging of treatment time. After 12 and 24 weeks of treatment, the aforementioned indices in the observation group were lower than those in the control group (P<0.05). After treatment, the total effective rate of Traditional Chinese Medicine syndrome efficacy of the observation group was higher than that of the control group (P<0.05). There was no statistically significant difference in the incidence rate of adverse reactions during treatment between patients of the two groups (P>0.05). Conclusion The clinical efficacy of Xuefu Zhuyu Decoction combined with entecavir for the treatment of patients with hepatitis B compensated liver cirrhosis in blood stasis and collaterals blocking type is superior to that of single entecavir, which can effectively decrease expressions of inflammatory cytokines, improve liver function, exerting relatively favorable safety.

无